会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • PLASMA MICRORNAS FOR THE DETECTION OF EARLY COLORECTAL CANCER
    • 等离子体微波技术检测早期大肠癌
    • WO2013093635A3
    • 2013-09-06
    • PCT/IB2012003035
    • 2012-10-20
    • HOSPITAL CLINIC BARCELONACT DE INVESTIGACION BIOMEDICA EN RED DE ENFERMEDADES HEPATICAS Y DIGESTIVAS
    • GIRONELLA I COS MERITXELLLOZANO SALVATELLA JUAN JOSECASTELLS I GARANGOU ANTONIGIRALDEZ MARIA DOLORES
    • C12Q1/68
    • C12Q1/6886C12Q1/6809C12Q2600/118C12Q2600/136C12Q2600/158C12Q2600/16C12Q2600/178
    • The present invention relates in general to the field of colorectal cancer detection, and more particularly, to plasma microRNAs for the detection of early colorectal cancer. Specifically, the present invention includes methods, kits and biomarkers for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: A method for diagnosing or detecting colorectal neoplasia in a human subject comprising the steps of: obtaining one or more biological samples from the subject suspected of suffering from colorectal neoplasia; measuring an overall expression pattern or level of one or more microRNAs obtained from the one or more biological samples of the subject; and comparing the overall expression pattern of the one or more microRNAs from the biological sample of the subject suspected of suffering from colorectal neoplasia with the overall expression pattern of the one or more microRNAs from a biological sample of a normal subject, wherein the normal subject is a healthy subject not suffering from colorectal neoplasia, wherein overexpression of a combination of miR19a and miR19b, or miR19a and miR19b and miR15b is indicative of colorectal cancer.
    • 本发明一般涉及结肠直肠癌检测领域,并且更具体地涉及用于检测早期结肠直肠癌的血浆微RNA。 具体而言,本发明包括用于诊断或检测人类受试者中的结直肠瘤形成的方法,试剂盒和生物标志物,其包括以下步骤:用于诊断或检测人类受试者中的结肠直肠瘤形成的方法,其包括以下步骤:从一个或多个受试者获得一种或多种生物样品 怀疑患有结直肠瘤形成的受试者; 测量从受试者的一种或多种生物样品获得的一种或多种微RNA的整体表达模式或水平; 并比较来自怀疑患有结肠直肠瘤形成的受试者的生物样品的一种或多种微RNA的总体表达模式与来自正常受试者的生物样品的一种或多种微RNA的总体表达模式,其中正常受试者是 未患有结肠直肠瘤形成的健康受试者,其中miR19a和miR19b或miR19a和miR19b和miR15b的组合的过度表达指示结肠直肠癌。